

Pogue et al.  
Serial No.: 10/660,860  
Page 2 of 3

### Listing of the Claims

This listing of claims will replace all prior versions and listing of the claims in the application:

Claim 1. A DNA construct containing an infectious clone of an RNA virus containing a hairpin sequence corresponding to a gene encoded within the nucleus of the target host, said hairpin sequence being a sequence fragment of greater than 20 bp in length where the sequence fragment in the sense orientation is followed by different sequence fragment, derived from the first in the reverse complement orientation, with: no intervening sequence; or an intervening sequence of no greater than the collective length of the two sequence fragments comprising the hairpin.

Claim 2. A cytoplasmic inhibition of nuclear gene expression resulting from hairpin RNA expression from an RNA virus genome in accordance with claim 1.

Claim 3. (Withdrawn)

Claim 4. (Withdrawn)

Claim 5. A method for determining nuclear gene function through a process of cytoplasmic inhibition of gene expression following infection with an RNA virus genome containing a hairpin nucleotide sequence in accordance with claim 1.

Claim 6. A hairpin sequence vector in accordance with claim 1 comprising a tobacco mosaic virus.

Claim 7. A hairpin sequence vector in accordance with claim 1 comprising a barley striped mosaic virus genome.

Pogue et al.  
Serial No.: 10/660,860  
Page 3 of 3

Claim 8. A virus vector for cytoplasmic gene silencing applications, in accordance with claim 1, comprising a very short, yet highly active gene silencing inducer, such as said hairpin sequence, wherein said virus vector exhibits improved genetic stability.

Claim 9. A vector as specified in claim 1, that contains a 20-30 nucleotide hairpin sequence for infection of mammalian cells and delivery of hairpin RNA to the cytosol for cytoplasmic gene inhibition.

Claim 10. A vector as specified in claim 9, derived from the alphavirus, rubivirus virus families.

Claims 3 and 4 have been withdrawn without prejudice to the filing of a divisional application, leaving claims 1-2 and 5-10 currently pending in the application.

If needed, applicants petition for an extension of time under the provisions of 37 CFR 1.136(a) for sufficient time to accept this response. The commissioner hereby is authorized to charge payment of any fees under 37 CFR § 1.17, which may become due in connection with the instant application or credit any overpayment to Deposit Account No.500933.

Respectfully submitted,



Wayne P. Fitzmaurice  
Reg. No. 58,274

Date: May 30, 2006

Wayne P. Fitzmaurice  
Senior Director  
Large Scale Biology Corporation  
3333 Vaca Valley Parkway, Suite 1000  
Vacaville, CA 95688  
707-469-2395 tel.  
707 454-0691 Fax.  
E-MAIL wayne.fitzmaurice@lsbc.com